Omecamtiv mecarbil is a novel cardiac myosin activator that increases contractility in heart muscle through selectively activating the enzyme myosin ATPase. This results in increased cardiac contractility without impacting intracellular calcium, unlike many currently available inotropic agents. Changes in intracellular calcium are thought to be associated with adverse clinical effects in heart failure patients.
Cytokinetics’ strong strategic partnerships with larger companies such as Amgen has placed omecamtiv mecarbil in an ideal position to have optimum market penetration in the US, Japan, and EU. The drug’s ability to increase contractility without affecting intracellular calcium places it at a clear advantage to other inotropic agents such as digoxin, usage of which has declined due to safety issues associated with changes in intracellular calcium. Despite this promising mode of action, which may reduce side effects, Amgen will still need to provide strong clinical data in order to convince physicians of its benefit.
LIST OF FIGURES
7 Figure 1: Omecamtiv mecarbil for chronic heart failure – SWOT analysis
8 Figure 2: Datamonitor Healthcare’s drug assessment summary of omecamtiv mecarbil for chronic heart failure
9 Figure 3: Datamonitor Healthcare’s drug assessment summary of omecamtiv mecarbil for chronic heart failure
11 Figure 4: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Omecamtiv mecarbil drug profile
6 Table 2: Omecamtiv mecarbil Phase III study in chronic heart failure
6 Table 3: Omecamtiv mecarbil Phase II data in chronic heart failure
12 Table 4: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.